

# Mimicking the chemistry of natural eumelanin synthesis: the KE sequence in polypeptides and in proteins allows for a specific control of nanosized functional polydopamine formation.

*Camille Bergtold*<sup>1,2,\*</sup>, *Daniel Hauser*<sup>3,\*</sup>, *Alain Chaumont*<sup>4</sup>, *Salima Elyakhlifi*<sup>2</sup>, *Mihaela Mateescu*<sup>1</sup>, *Florent Meyer*<sup>1,2</sup>, *Marie-Hélène Metz-Boutigue*<sup>1,2</sup>, *Benoît Frisch*<sup>5</sup>, *Pierre Schaaf*<sup>1,6</sup>, *Driss Ihiawakrim*<sup>7</sup>, *Ovidiu Ersen*<sup>7</sup>, *Christophe A. Monnier*<sup>3</sup>, *Alke Petri-Fink*<sup>3</sup>, *Barbara Rothen-Rutishauser*<sup>3</sup> & *Vincent Ball*<sup>1,2,#</sup>

1: Université de Strasbourg, Faculté de Chirurgie Dentaire, 8 rue Sainte Elisabeth, 67000 Strasbourg, France.

2: Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1121, 11 rue Humann, 67085 Strasbourg Cedex, France.

3: Adolphe Merkle Institute, University of Fribourg, 4 Chemin des Verdiers, CH-1700 Fribourg, Switzerland.

4 : Faculté de Chimie, Chimie de la Matière Complexe, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7140, 4 rue Blaise Pascal, 67081, Strasbourg, France.


5: Université de Strasbourg, Faculté de Pharmacie, Laboratoire de Conception et application de molécules bioactives.

6: Centre National de la Recherche Scientifique, Institut Charles Sadron, Unité Propre 22, 23 rue du Loess, 67034 Strasbourg, France.


7: Centre National de la Recherche Scientifique, Institut de Physique et de Chimie des Matériaux, Unité Mixte de Recherche 7504, 23 rue du Loess, 67034, Strasbourg, Cedex 2, France.

email: vball@unistra.fr


## Supporting Information




**Figure SI 1:** Size exclusion (SEC) chromatograms of the GGKKEGG, GGKKGEGG and GGKGGEGG peptides (first row) and of the same peptides with added dopamine in the presence of Tris buffer (pH = 8.5). The SEC were taken 16h after mixing dopamine with the considered peptides. The detection wavelength was set at 214 nm.




**Figure SI 2:** Schematic representation of the dopamine molecule and the RESP charges used during MD simulation.



**Figure SI 3:** Absorbance of PDA films deposited on quartz slides recorded at  $\lambda=500$  nm as a function of the oxidation time in the presence of dopamine at  $2\text{mg.mL}^{-1}$  (Tris buffer  $50$  mM, pH =  $8.5$ ), in the absence of lysozyme (●) and in the presence of lysozyme at  $0.5$  (■) and  $1$  (■)  $\text{mg.mL}^{-1}$ .




**Figure SI 4:** Absorbance of PDA films deposited on quartz slides recorded at  $\lambda=500$  nm as a function of the oxidation time in the presence of dopamine at  $2\text{mg.mL}^{-1}$  (Tris buffer 50 mM, pH = 8.5), in the absence of  $\alpha$  lactalbumin (●) and in the presence of  $\alpha$  lactalbumin at  $1.0\text{ mg.mL}^{-1}$  (■).



**Figure SI 5:** A : Absorbance of PDA films deposited on quartz slides recorded at  $\lambda=500$  nm as a function of the oxidation time in the presence of dopamine at  $2\text{mg.mL}^{-1}$  (Tris buffer  $50$  mM,  $\text{pH} = 8.5$ ), in the absence of human fibrinogen ( $\bullet$ ) and in the presence of human fibrinogen at  $0.2$   $\text{mg.mL}^{-1}$  ( $\blacksquare$ ) and at  $2$   $\text{mg.mL}^{-1}$  ( $\blacksquare$ ).

B: Evolution of the hydrodynamic diameter of PDA@fibrinogen particles after 24 h of oxidation ( $2$   $\text{mg.mL}^{-1}$  dopamine in the presence of  $50$  mM Tris buffer at  $\text{pH} = 8.5$ ) as a function of the protein concentration. The protein + PDA mixture was dialyzed before the light scattering experiments. ( $\circ$ ) and ( $\bullet$ ) correspond to the smaller and larger particles with relative fractions of about  $60$  and  $40$  % (in number of particles)



**Figure SI 6:** A : Absorbance of PDA films deposited on quartz slides recorded at  $\lambda=500 \text{ nm}$  as a function of the oxidation time in the presence of dopamine at  $2 \text{ mg.mL}^{-1}$  (Tris buffer  $50 \text{ mM}$ ,  $\text{pH} = 8.5$ ), in the absence of glucose oxidase + peroxidase (●) and in the presence of a mixture of both proteins at  $0.5 \text{ mg.mL}^{-1}$  each (●).

B: Evolution of the hydrodynamic diameter of PDA@GOX+POX particles after 24 h of oxidation ( $2 \text{ mg.mL}^{-1}$  dopamine in the presence of  $50 \text{ mM}$  Tris buffer at  $\text{pH} = 8.5$ ) as a function of the protein concentration. The protein + PDA mixture was dialyzed before the light scattering experiments. (○) and (●) correspond to the smaller and larger particles with relative fractions of about 60 and 40 % (in number of particles) in the absence of proteins and to 100 % in the presence of GOX ( $0.5 \text{ mg.mL}^{-1}$ ) and POX ( $0.5 \text{ mg.mL}^{-1}$ ).

## Human Serum Albumin

```
10          20          30          40          50
QFPTDYDEGQ DDRPKVGLGA RGHHPYDKKK EEAPSLRPVP PPISGGGYRA
60          70          80          90          100
RPATATVGQK KVERKPPDAD GCLHADPD LG VLCPTGCKLQ DTLVRQERPI
110         120         130         140         150
RKSIEDLRNT VDSVSRTSSS TFQYITLLKN MWKGRQNQVQ DNENVVNEYS
160         170         180         190         200
SHLEKHQLYI DETVKNNIPT KLRVLR SILE NLRSKI QKLE SDVSTQMEYC
210         220         230         240         250
RTPCTVTCNI PVVSGKECEK IIRNEGETSE MYLIQPEDSS KPYRVYCDMK
260         270         280         290         300
TEKGGWTVIQ NRQDGSVDFG RKWDPYKQGF GNIATNAEGK KYCGVPGEYW
310         320         330         340         350
LGNDRISQLT NMGPTKLLIE MEDWKGDKVT ALYEGFTVQN EANKYQLSVS
360         370         380         390         400
KYKGTAGNAL IEGASQLVGE NRTMTIHNSM FFSTYDRDND GWKTTDPRKQ
410         420         430         440         450
CSKEDGGGWW YNRCHAANPN GRYYWGGAYT WDMAKHGTDD GVVWMNWQGS
460
WYSMKKMSMK IRPYFPEQ
```



## Glucose oxidase (Aspergillus Niger)

```
10          20          30          40          50
MQTLLVSSLV VSLAAALPHY IRSNGIEASL LTDPKDVSGR TVDYIIAGGG
60          70          80          90         100
LTGLTTAARL TENPNISVLV IESGSYESDR GPIIEDLNAY GDIFGSSVDH
110         120         130         140         150
AYETVELATN NQTALIRSGN GLGGSTLVNG GTWTRPHKAQ VDSWETVFGN
160         170         180         190         200
EGWNWDNVAA YSLQAERARA PNAKQIAAGH YFNASCHGVN GTVHAGPRDT
210         220         230         240         250
GDDYSPIVKA LMSAVEDRGV PTKKDFGCGD PHGVSMFPNT LHEDQVRSDA
260         270         280         290         300
AREWLLPNYQ RPNLQVLTGQ YVGKVLLSQN GTTPRAVGVE FGTHKGNTHN
310         320         330         340         350
VYAKHEVLLA AGSAVSPTIL EYSGIGMCSI LEPLGIDTVV DLPVGLNLQD
360         370         380         390         400
QTTATVRSRI TSAGAGQGQA AWFATFNETF GDYSEKAHEL LNTKLEQWAE
410         420         430         440         450
EAVARGGFHN TTALLIQYEN YRDWIVNHNV AYSELFLDTA GVASFDVWDL
460         470         480         490         500
LPFTRGYVHI LDKDPYLHFF AYDPQYFLNE LDLLGQAAAT QLARNISNSG
510         520         530         540         550
AMQTYFAGET IPGDNLAYDA DLSAWTEYIP YHFRPNYHGV GTCSMMPKEM
560         570         580         590         600
GGVVDNAARV YGVQGLRVID GSIPTQMSS HVMTVIFYAMA LKISDAILED
```

YASMQ

## Horseradish peroxidase

```
10          20          30          40          50
MAMSYSIRVL TFLMLISLMA VTLNLLSTAE AKKPRRDVPI VKGLSWNFYQ
60          70          80          90         100
RACPKVEKII KELKKVFKR DIGLAAAILR IHFHDCFVQG CEASVLLAGS
110         120         130         140         150
ASGPGEQSSI PNLTLRQQAF VVINNLRALV QKQCGQVVSC SDILALAARD
160         170         180         190         200
SIVLSGGPDY AVPLGRDLSL AFATPETTLA NLPPPFANAS QLISDFNDRN
210         220         230         240         250
LNITDLVALS GGHTIGIAHC PSFTDRLYPN QDPTMNKSFA NSLKRTCPTA
260         270         280         290         300
NSSNTQVNDI RSPDVFNDKY YVDLMNRQGL FTSDQDLFVD KRTRGIVESF
310         320         330         340         350
AIDQNLFFDH FTVAMIKMGQ MSVLTGTQGE IRSNCSARNT ASFISVLEEG
```

IVEEALSMI


## Hemoglobin $\alpha$ chain

```

      10          20          30          40          50
MVLSPADKTN VKAAWGKVGA HAGEYGAEAL ERMFLSFPTT KTYFPHFDLS
      60          70          80          90          100
HGSAQVKGHG KKVADALTN VAHVDDMPNA LSALSDLHAH KLRVDPVNFK
      110         120         130         140
LLSHCLLVTL AAHLPAEFTP AVHASLDKFL ASVSTVLTSK YR
  
```

**Figure SI 7:** Amino acid sequences of the proteins used to control the oxidation of dopamine and its assembly in PDA. The KE sequence has been highlighted in red when present.

The sequences are extracted from UniprotKB.



**Figure SI 8 :** A : Absorbance of PDA films deposited on quartz slides recorded at  $\lambda=500$  nm as a function of the oxidation time in the presence of dopamine at  $2\text{mg.mL}^{-1}$  (Tris buffer 50 mM, pH = 8.5), in the absence of human hemoglobin (●) and in the presence of human hemoglobin at  $0.2\text{mg.mL}^{-1}$  (■).

B: Evolution of the hydrodynamic diameter of PDA@hemoglobin particles after 24 h of oxidation ( $2\text{mg.mL}^{-1}$  dopamine in the presence of 50 mM Tris buffer at pH = 8.5) as a function of the protein concentration. The protein + PDA mixture was dialyzed before the light scattering

experiments. (○) and (●) correspond to the smaller and larger particles with relative fractions of about 60 and 40 % (in number of particles)